Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Drug-drug Interactions of ENV-101 in Healthy Participants
NCT07454291Phase 1Recruiting
- Sponsor
- Endeavor BioMedicines
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taladegib in idiopathic pulmonary fibrosis (IPF) (4 cohorts), sponsored by Endeavor BioMedicines. Primary endpoints: Maximum blood concentration at Day 27, Time of maximum blood concentration at Day 27 and 7 more. Started Apr 2026; status: recruiting.
02
Drugs
taladegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07454291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454291.